Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of sorafenib and bortezomib in
treating patients with advanced cancer. Sorafenib and bortezomib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop
the growth of cancer cells by blocking blood flow to the cancer